Cargando...
Marked response to nab-paclitaxel in EGFR mutated lung neuroendocrine carcinoma: A case report
RATIONALE: Lung cancer is the leading cause of cancer-related death in the world. Tyrosine kinase inhibitors (TKIs), which target mutated epidermal growth factor receptor (EGFR), have been the first-line treatment of late-stage lung adenocarcinoma harboring EGFR mutation. EGFR mutations are mostly i...
Guardado en:
| Publicado en: | Medicine (Baltimore) |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Wolters Kluwer Health
2017
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5457885/ https://ncbi.nlm.nih.gov/pubmed/28538405 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000006985 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|